Targeted binding agents directed to uPAR and uses thereof
Targeted binding agents directed to the antigen uPAR and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen uPAR. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.
1. An isolated antibody, or binding fragment thereof, that specifically binds to urokinase-type plasminogen activator receptor (uPAR) and inhibits binding of urokinase-type plasminogen activator (uPA) to urokinase-type plasminogen activator receptor (uPAR), wherein said antibody is a monoclonal antibody having the amino acid sequence of the antibody produced by the hybridoma deposited at ATCC under Accession Number PTA-7475.
2. An isolated antibody, or binding fragment thereof, that specifically binds to uPAR, wherein said antibody comprises a heavy chain polypeptide comprising the sequence of SEQ ID NO.: 26 or SEQ ID NO: 26 comprising any one of the combinations of residues indicated by each row of Table 15, and a light chain polypeptide comprising the sequence of SEQ ID NO: 28, or SEQ ID NO: 28 comprising any one of the combinations of residues of SEQ ID NO: 28 indicated by each row of Table 14.
3. The antibody of claim 2 , wherein said antibody comprises a heavy chain polypeptide comprising the sequence of SEQ ID NO: 26.
4. The antibody of claim 2 , wherein said antibody comprises a light chain polypeptide comprising the sequence of SEQ ID NO: 28.
5. An isolated monoclonal antibody or binding fragment thereof that binds to the same epitope on uPAR as the antibody of any of claims 1 and 2 - 4 .
6. An isolated antibody, or binding fragment thereof, that specifically binds to urokinase-type plasminogen activator receptor (uPAR), wherein the antibody comprises:
a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of TNYMN (SEQ ID NO: 94);
a heavy chain complementarity determining region 2 (CDR2) having the amino acid sequence of IIYTGGSTSYADSVKG (SEQ ID NO: 95);
a heavy chain complementarity determining region 3 (CDR3) having the amino acid sequence of EIAVAGYYGMDV (SEQ ID NO: 96);
a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of RASQGIRNDLG (SEQ ID NO: 103);
a light chain complementarity determining region 2 (CDR2) having the amino acid sequence of AASSLQS (SEQ ID NO: 104); and
a light chain complementarity determining region 3 (CDR3) having the amino acid sequence of LQHNSYPLT (SEQ ID NO: 105).
7. The antibody according to claim 6 , wherein said antibody is a fully human monoclonal antibody.
8. A conjugate comprising the antibody of any one of claims 1 , 2 - 4 , 6 and 7 or a binding fragment thereof, and a therapeutic agent.
9. The conjugate of claim 8 , wherein the therapeutic agent is a toxin.
10. The conjugate of claim 8 , wherein the therapeutic agent is a radioisotope.
11. The antibody of claim 2 , wherein one or more framework residues has been mutated to yield the corresponding germline residue at that position.
12. The antibody of any of claims 1 , 2 , 4 , 6 and 7 , wherein said antibody is selected from the group consisting of Fab, Fab′, F(ab′)2 and Fv.
13. A composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.
14. A composition comprising the antibody of any one of claims 2 , 4 , and 6 and a pharmaceutically acceptable carrier.
15. A composition comprising the antibody of claim 6 and a pharmaceutically acceptable carrier.
16. A conjugate comprising the antibody of claim 5 or a binding fragment thereof, and a therapeutic agent.
17. The antibody of claim 5 , wherein said antibody is selected from the group consisting of Fab, Fab′, F(ab′)2 and Fv.
18. A composition comprising the antibody of claim 5 and a pharmaceutically acceptable carrier.